UK Diabetic Foot Ulcer Biologics Market Size & Outlook
Related Markets
UK diabetic foot ulcer biologics market highlights
- The UK diabetic foot ulcer biologics market generated a revenue of USD 113.4 million in 2024 and is expected to reach USD 166.6 million by 2030.
- The UK market is expected to grow at a CAGR of 6.6% from 2025 to 2030.
- In terms of segment, skin substitutes was the largest revenue generating product in 2024.
- Tissue-Engineered Products is the most lucrative product segment registering the fastest growth during the forecast period.
Diabetic foot ulcer biologics market data book summary
| Market revenue in 2024 | USD 113.4 million |
| Market revenue in 2030 | USD 166.6 million |
| Growth rate | 6.6% (CAGR from 2025 to 2030) |
| Largest segment | Skin substitutes |
| Fastest growing segment | Tissue-Engineered Products |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Skin Substitutes, Growth Factors, Tissue-Engineered Products |
| Key market players worldwide | Organogenesis Holdings Inc Class A, Tissue Regenix, BioTissue, Integra Lifesciences Holdings Corp, MiMedx Group Inc, ConvaTec Inc., Coloplast A/S ADR, Smith & Nephew PLC, Stedical Scientific, Zimmer Biomet Holdings Inc, Gunze |
Other key industry trends
- In terms of revenue, UK accounted for 5.7% of the global diabetic foot ulcer biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany diabetic foot ulcer biologics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 223.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Diabetic Foot Ulcer Biologics Market Scope
Diabetic Foot Ulcer Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Gunze | View profile | 5001-10000 | Osaka, Osaka, Japan, Asia | https://www.gunze.co.jp/ |
| Stedical Scientific | View profile | - | Carlsbad, California, United States, North America | https://www.stedical.com/ |
| ConvaTec Inc. | View profile | - | - | - |
| Tissue Regenix | View profile | 51-100 | York, York, United Kingdom, Europe | http://www.tissueregenix.com |
| BioTissue | View profile | 1-10 | Genève, Geneve, Switzerland, Europe | http://www.biotissue.ch |
| Organogenesis Holdings Inc Class A | View profile | 862 | 85 Dan Road, Canton, MA, United States, 02021 | https://www.organogenesis.com |
| MiMedx Group Inc | View profile | 895 | 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062 | https://www.mimedx.com |
| Smith & Nephew PLC | View profile | 18452 | Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, United Kingdom, WD18 8YE | https://www.smith-nephew.com |
| Coloplast A/S ADR | View profile | 15930 | Holtedam 1-3, Humlebaek, Denmark, DK-3050 | https://www.coloplast.com |
| Integra Lifesciences Holdings Corp | View profile | 3946 | 1100 Campus Road, Princeton, NJ, United States, 08540 | https://www.integralife.com |
| Zimmer Biomet Holdings Inc | View profile | 18000 | 345 East Main Street, Warsaw, IN, United States, 46580 | https://www.zimmerbiomet.com |
UK diabetic foot ulcer biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetic foot ulcer biologics market will help companies and investors design strategic landscapes.
Skin substitutes was the largest segment with a revenue share of 54.23% in 2024. Horizon Databook has segmented the UK diabetic foot ulcer biologics market based on skin substitutes, growth factors, tissue-engineered products covering the revenue growth of each sub-segment from 2018 to 2030.
UK diabetic foot ulcer biologics market is driven by strategic partnerships, product innovations, and expansion of R&D and manufacturing facilities by key industry players.
Companies are actively enhancing their market presence through collaborations, such as PolyNovo Ltd’s acquisition of exclusive distribution and sales rights for SUPRATHEL in May 2024, which expands access to advanced epidermal skin substitutes for wound healing.
These partnerships are expected to increase the availability of innovative biologic treatments in the UK, improving DFU management and driving market growth. In addition, the focus on advanced wound care solutions and expanding healthcare infrastructure further supports the adoption of DFU biologics in the region.
Reasons to subscribe to UK diabetic foot ulcer biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK diabetic foot ulcer biologics market databook
-
Our clientele includes a mix of diabetic foot ulcer biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK diabetic foot ulcer biologics market , including forecasts for subscribers. This country databook contains high-level insights into UK diabetic foot ulcer biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK diabetic foot ulcer biologics market size, by product, 2018-2030 (US$M)
UK Diabetic Foot Ulcer Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
